ai vax works success announ close

when the CSIRO farrrrked up the initial trial for imugene a crucial few words were said.

18 October 2004, Sydney: A pilot trial of the first Avian Influenza vaccine candidate did not demonstrate sufficient protection against disease caused by the H5N1 strain of bird flu. A small number of vaccinated chickens survived infection, however the survival percentage was small.


This was with a batch of vaccine that didnt express the corrective gene.
the reality is domestic foul do not survive h5n1 for more than 24 hours. Its mortality is 99.99%
sure ducks and turkeys are more reilient and have survived but not chooks.

well when the current vax was made it was tested in vito and yes it expresses correctly.
A robust immune response can be expected and the fact is the trial has been going 3 weks now and if it was a flop you would get the vibe.

Imu directors are very clever b/c they know the importance of a trial in the USA. the media will be in a frenzy when the successful results are issued.

The share price will escalate to around $1.70 rapidly
===================================
Bird Flu Vaccine Back on Track
Investigations into the failure of the Avian Influenza Vaccine pilot trial reveal a defect in the initial batch of the vaccine
17 November 2004, Sydney: Imugene (ASX IMU) today announced that analysis of the initial batch of the test vaccine used in the recent Avian Influenza pilot trial (reported in October 2004) revealed a batch defect which is now being corrected. Whilst uncommon, technical defects in early batches can occur with this technology and can be resolved.
“The pilot trial results were unexpected. We now know that it was the batch rather than the actual vaccine that was the problem with the pilot trial,” stated Dr Warwick Lamb, Managing Director of Imugene. “The gene used is the correct protective gene and once we get correct expression of this gene, we expect effective protection against the Avian Influenza.”
“Reconstruction of a new batch of the vaccine will soon commence and trials are expected to be underway early in 2005. The new batch will be tested at several stages to ensure that the defect has been corrected. This will ensure that the protective gene will express as expected,” said Dr Lamb. “With this news and the recent success in gaining a $250,000 BIF grant to develop the Avian Influenza Vaccine, we remain very optimistic that we can develop an effective vaccine against bird flu.”
========================================
$1.70 rapidly $1.70 rapidly $1.70 rapidly $1.70 rapidly
$1.70 rapidly $1.70 rapidly $1.70 rapidly $1.70 rapidly